A Phase 3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of 2000 mg/kg of Trappsol® Cyclo™ (Hydroxypropyl-β-cyclodextrin) and Standard of Care Compared to Placebo and Standard of Care in Patients with Niemann-Pick Disease Type C1

drug protocol number
CTD-TCNPC-301
drug sponsor
Cyclo Therapeutics, Inc
drug study
Hydroxypropyl-β-cyclodextrin (Trappsol® Cyclo™)
drug trial site
King Faisal Specialist Hospital and Research Center (Riyadh)
drug status
Ongoing
drug phase